PARIS--(BUSINESS WIRE)--Regulatory News:
The Combined Shareholders’ Meeting of Ipsen S.A. (Euronext: IPN; ADR: IPSEY), chaired by Marc de Garidel, Chairman and Chief Executive Officer, was held today, in the presence of the members of the Board of Directors and the Group Executive Management.
The Shareholders’ Meeting approved all the resolutions submitted by the Board of Directors and in particular the distribution of €0.85 dividend per share to be paid on 6 June 2016 (ex-dividend date 2 June 2016) and the renewal of the terms of office as Directors of Mrs. Carol Xueref and the company Mayroy SA.
During the Meeting, Marc de Garidel and Aymeric Le Chatelier, Executive Vice President, Chief Financial Officer, presented, in particular, the major events and financial results for 2015 as well as the 2016 outlook and 2016 first quarter sales.
Ipsen is a global specialty-driven pharmaceutical group with total sales exceeding €1.4 billion in 2015. Ipsen sells more than 20 drugs in more than 115 countries, with a direct commercial presence in more than 30 countries. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its fields of expertise cover oncology, neurosciences and endocrinology. Ipsen’s commitment to oncology is exemplified through its growing portfolio of key therapies improving the care of patients suffering from prostate cancer, bladder cancer and neuro-endocrine tumors. Ipsen also has a significant presence in primary care. Moreover, the Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins, located in the heart of the leading biotechnological and life sciences hubs (Les Ulis/Paris-Saclay, France; Slough/Oxford, UK; Cambridge, US). In 2015, R&D expenditure totaled close to €193 million. The Group has more than 4,600 employees worldwide. Ipsen’s shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the “Service de Règlement Différé” (“SRD”). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit www.ipsen.com.